FDA Approval of Psychedelics, Coming Soon?

A recent report from the Substance Abuse and Mental Health Services Administration (SAMHSA) encourages U.S. states to begin preparing for possible approval of psychedelic therapies by the Food and Drug Administration.

The transition from research to clinics is moving faster than those in the field anticipated even five years ago, the report notes, and being proactive is important.

“The question is not whether individuals in a particular state will use psychedelics, but whether they will do so in regulated, safe contexts or in underground networks,” the report reads.

Read more

Psilocybin, Brain Health and Longevity

In the second wave of psychedelic research, there are multiple trials taking place across the world.

This includes looking into their potential use to treat end-of-life anxiety and depression in the terminally ill (at the US’s John Hopkins University and NYU), for smoking cessation, alcoholism, anorexia, OCD, asthma, longevity and pain syndromes, as well as seven separate trials worldwide into the use of psilocybin to treat depression.

Read more